✦ LIBER ✦

Phase II trial of hu14.18-IL2 for patients with metastatic melanoma

✍ Scribed by Mark R. Albertini, Jacquelyn A. Hank, Brian Gadbaw, Jordan Kostlevy, Jennifer Haldeman, Heidi Schalch, Jacek Gan, KyungMann Kim, Jens Eickhoff, Stephen D. Gillies, Paul M. Sondel

Book ID: 118781396
Publisher: Springer-Verlag
Year: 2012
Tongue: English
Weight: 319 KB
Volume: 61
Category: Article
ISSN: 0340-7004
DOI: 10.1007/s00262-012-1286-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I/II open-label study of the biolo

Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma

✍ Antoni Ribas; John M Kirkwood; Michael B Atkins; Theresa L Whiteside; William Go 📂 Article 📅 2009 🏛 BioMed Central 🌐 English ⚖ 784 KB

Phase II trial of fotemustine in patient

Phase II trial of fotemustine in patients with metastatic malignant melanoma

✍ Carla I. Falkson; Geoffrey Falkson; Hendré C. Falkson 📂 Article 📅 1994 🏛 Springer US 🌐 English ⚖ 318 KB

Phase II trial of imatinib mesylate in p

Phase II trial of imatinib mesylate in patients with metastatic melanoma

✍ Kim, K B; Eton, O; Davis, D W; Frazier, M L; McConkey, D J; Diwan, A H; Papadopo 📂 Article 📅 2008 🏛 Nature Publishing Group 🌐 English ⚖ 305 KB

A phase II trial of arsenic trioxide in

A phase II trial of arsenic trioxide in patients with metastatic melanoma

✍ Kevin B. Kim; Agop Y. Bedikian; Luis H. Camacho; Nicholas E. Papadopoulos; Cecil 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 170 KB 👁 2 views

Outpatient combination chemoimmunotherap

Outpatient combination chemoimmunotherapy for patients with metastatic melanoma : Results of a Phase I/II trial

✍ Mohammed Kashani-Sabet; Richard W. Sagebiel; Henry E. Collins; Alan B. Glassberg 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 75 KB 👁 2 views

## BACKGROUND. Few studies have examined the feasibility, safety, and efficacy of an outpatient biochemotherapy regimen of low dose, subcutaneously administered interleukin-2 (IL-2) for patients with metastatic (Stage IV) melanoma. ## METHODS. Nineteen patients were treated with intravenous cispl

Phase II trial of carbetimer in metastat

Phase II trial of carbetimer in metastatic melanoma

✍ Walter D. Y. Quan; Malcolm S. Mitchell 📂 Article 📅 1993 🏛 Springer US 🌐 English ⚖ 230 KB